Uniphar plots further M&A deals and reiterates medium-term target to hit €200m in profits

The listed healthcare group said it achieved steady growth in 2023 and is forecasting double-digit expansion of its new pharma division this year

Uniphar first listed on the stock market in 2019 and its shares have more than doubled in that time to value the group at more than €700 million

Uniphar, the Irish listed healthcare services group, has reiterated its medium-term target to hit €200 million in annual profits as its pharma and medtech arms continue to see strong growth.

In a trading update issued to investors on Tuesday, Uniphar said it recorded organic profit growth “in excess of 5 per cent” last year, while Ebitda was in line with market expectations – implying full year earnings of around €115 million.

Listed on the Dublin ...